Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Official Title

A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment


The purpose of this study is to evaluate the efficacy and safety of imetelstat in transfusion dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to erythropoiesis-stimulating agent (ESA) treatment.

Trial Description

Primary Outcome:

  • Percentage of participants without any red blood cell (RBC) transfusion during any consecutive 8 week period
Secondary Outcome:
  • Number of Participants with Adverse Events (AEs)
  • Percentage of participants without any red blood cell (RBC) transfusion during any consecutive 24 week period
  • Time to the 8-week RBC transfusion independence (TI)
  • Duration of RBC TI
  • Percentage of Participants with hematologic improvement
  • Percentage of Participants with Complete remission (CR) or Partial remission (PR) as Per International Working Group (IWG) Response Criteria 2006
  • Overall survival
  • Progression Free Survival (PFS)
  • Time to Progression to Acute Myeloid Leukemia
  • Percentage of Participants with Transfusion
  • Amount of Transfusions
  • Percentage of Participants receiving any myeloid growth factors
  • Maximum Observed Plasma Concentration (Cmax)
  • Area under the drug concentration-plasma time curve from time zero to last measurable concentration (AUC0-t)
  • Percentage of Participants with antibodies to imetelstat
  • Medical Resource Utilization Data in Part 2
  • Assessment of Functional Assessment of Cancer Therapy- Anemia-Related Effects (FACT-An) in Part 2
  • Assessment of EuroQol 5 Dimension Questionnaire (EQ-5D-5L) in Part 2
  • Assessment of Quality of Life in Myelodysplasia Scale (QUALMS) in Part 2
  • Assessment of Participant Global Impression of Change (PGIC) in Part 2
  • Change From Baseline in QTc Interval at Day 1 of Part 2
This is a Phase 2/3, multicentre study of imetelstat that consists of 2 parts. Part 1 is an open-label, single-arm design to assess the efficacy and safety of imetelstat. Approximately 55 participants will be enrolled in Part 1, including the expansion cohort, and be followed-up for safety, hematologic improvement and reduction in transfusion requirement. Part 2 of the study will be initiated if data from Part 1 are supportive of a satisfactory benefit/risk profile. Part 2 is a double-blind, randomized design to compare the efficacy of imetelstat with placebo. Approximately 170 eligible participants will be randomized in a 2:1 ratio to receive either imetelstat or placebo, respectively. Each part of the study will consist of 3 phases: a Screening phase (up to 28 days); a treatment phase; and a post-treatment follow-up phase which will continue until death, lost to follow-up, withdrawal of consent, or the End of the Study (whichever occurs first). The End of the Study is defined as 2 years after the study entry of the last participant or anytime the sponsor terminates the study, whichever comes first.

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society